Arbios Appoints Dr. Philip Rosenthal and Dr. Robert S. Brown, Jr. to Its Scientific Advisory Board Top Thought Leaders in Liver Disease to Play Important Role in the Development Strategy for Arbios' Bioartificial Liver LOS ANGELES, June 24 /PRNewswire-FirstCall/ -- Arbios Systems, Inc. (OTC:ABOS) a biomedical device company developing proprietary liver assist devices for the treatment of liver failure, announced today that the Company has appointed Drs. Robert S. Brown, Jr., M.P.H. and Philip Rosenthal, to its Scientific Advisory Board. Commenting on these latest appointments, Amy Factor, Chief Executive Officer of Arbios, stated, "We are delighted to welcome Drs. Brown and Rosenthal to our Scientific Advisory Board. They are highly esteemed researchers and physicians in the liver disease arena, and were involved in the Phase II/III clinical trials of HepatAssist(TM), the predecessor version of our bioartificial liver, currently under development. As a result of their specific expertise, Drs. Brown and Rosenthal will play an important role in the development of our clinical and regulatory strategy for our bioartificial liver program. Dr. Brown is currently Associate Professor of Medicine & Surgery and Chief, Division of Hepatobiliary and Abdominal Transplant Surgery, Columbia University College of Physicians & Surgeons. In addition, he is currently Medical Director, Center for Liver Disease and Transplantation, New York Presbyterian Hospital -- a position he has held since 1998. Prior to joining Columbia University College of Physicians & Surgeons, Dr. Brown was Medical Director of Liver Transplantation at the University of North Carolina from 1996 to 1998. Dr. Brown's research is focused on clinical trials and epidemiologic research in liver failure and liver transplantation, particularly the outcomes of living donor liver transplantation, artificial liver support, and the management of viral hepatitis, areas in which he has had extensive research funding from the NIH and industry. Dr. Brown was a special section editor for Hepatology, serves on the editorial board for Liver Transplantation and is a reviewer for the journals: Transplantation, American Journal of Gastroenterology, New England Journal of Medicine, and the International Journal of Epidemiology, among others. He has published more than 80 original articles, reviews and book chapters. Dr. Brown is a fellow in the American College of Physicians and the American College of Gastroenterology, and is a member of the American Society of Transplantation, where he served as chair of the Liver and Intestine Committee and the American Association for the Study of Liver Disease (AASLD). He is currently co-chair of the United Network for Organ Sharing ad hoc living donor committee. Dr. Brown received his A.B. degree from Harvard University, his M.D. degree from New York University, and his M.P.H. from the Graduate School of Public Health at the University of California at Berkeley. He completed a Fellowship in Gastroenterology and Hepatology at the University of California, San Francisco. Dr. Rosenthal is an internationally renowned children's liver disease specialist. He currently serves as the Director of Pediatric Hepatology, Medical Director of the Pediatric Liver Transplant Program and a Professor of Pediatrics and Surgery at the University of California, San Francisco (UCSF). He joined the UCSF faculty in 1995, after serving as Professor of Pediatrics at the University of California, Los Angeles (UCLA). Dr. Rosenthal is a prolific author and a recipient of a number of professional honors and awards and is committed to clinical service, research and education. Currently, he is pursuing research on the pharmaceutical treatment of hepatitis B and C, genetics and immunology of biliary atresia, use of bioartificial liver support utilizing porcine hepatocytes for patients with fulminant liver failure, as well as researching the quality of life following liver transplantation in children. Dr. Rosenthal's professional services to the public include television, newspaper and radio interviews on various topics such as hepatitis A, B, and C, and liver transplants for local, national and international audiences. He is a consultant to organizations such as the American Liver Foundation, Parents of Kids with Infectious Diseases, the Alagille Syndrome Alliance, Studies of Pediatric Liver Transplantation (SPLIT), the Centers for Disease Control and Prevention (CDC) and the National Institute of Health (NIH). Dr. Rosenthal is board certified in Pediatrics and Pediatric Gastroenterology. He received a B.S. degree in Biology from the State University of New York at Albany and completed his medical training at Downstate Medical Center and the Albert Einstein Medical Center in New York, after which he completed a fellowship in pediatric gastroenterology at UCSF. Arbios Systems, Inc. is a biomedical device company that, through its wholly owned subsidiary, Arbios Technologies, Inc., is engaged in the discovery, acquisition and development of proprietary liver assist devices and new technologies useful in the diagnosis and treatment of acute liver failure. Arbios' products in development include SEPET(TM), a novel blood purification therapy and HepatAssist-2(TM), a bioartificial liver combining liver cell therapy and sorbent-based detoxification. This press release contains forward-looking statements that involve risks and uncertainties that could cause actual events or results to differ materially from the events or results described in the forward-looking statements, including risks or uncertainties related to obtaining clinical site approvals, manufacturing SEPET(TM) cartridges, enrolling patients, compliance with regulatory requirement, the results of the clinical tests to be conducted by the company, the need for subsequent substantial additional financing to complete clinical development of its products, and Arbios' ability to successfully market its products and technologies. These statements represent the judgment of Arbios' management as of this date and are subject to risks and uncertainties that could materially affect the company. The company does not undertake any obligation to publicly release the result of any revisions to such forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. SEPET(TM) and HepatAssist-2(TM) are trademarks of Arbios Technologies, Inc., the subsidiary of Arbios Systems, Inc. DATASOURCE: Arbios Systems, Inc. CONTACT: Amy Factor, Chief Executive Officer, +1-973-377-7665, of Arbios; or Paula Schwartz, Investors, +1-917-322-2216, or Pat Garrison, Media, +1-917-322-2567, both of RX Communications Group for Arbios Web site: http://www.arbios.com/

Copyright